Department of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Department of Applied Chemistry and Biotechnology, Faculty of Engineering, Okayama University, Okayama 700-8530, Japan.
Int J Mol Sci. 2018 Apr 23;19(4):1261. doi: 10.3390/ijms19041261.
T cell-deficient mice such as nude mice are often used to generate tumor xenograft for the development of anticancer agents. However, the functionality of the other immune cells including macrophages, dendritic cells (DCs), and myeloid-derived suppressor cells (MDSCs) in the xenograft are largely unknown. Macrophages and dendritic cells (DCs) acquire functionally distinct properties in response to various environmental stimuli; the interaction of these cells with MDSCs in tumor microenvironments regulates cancer progression. Nude mice are less likely to reject human cancer cells because of major histocompatibility complex (MHC) mismatches. The tumor microenvironment in a xenograft, comprising human and mouse cells, exhibits more complex bidirectional signaling and function than that of allograft. Here, we evaluated the differences of myeloid cells between them. Plasma interferon-γ and interleukin-18 concentrations in the xenograft tumor model after lipopolysaccharide (LPS) administration were significantly higher than those in the allograft tumor model. MHC class I, II, and CD80 expression levels were increased in CD11b⁺ and MDSC populations after LPS administration in the spleen of a xenograft tumor model but not in that of an allograft tumor model. Additionally, the number of CD80- and mannose receptor C type 1 (MRC1)-expressing cells was decreased upon LPS administration in the tumor of the xenograft tumor. These results suggest that functions of macrophages and DCs are sustained in the xenograft, whereas their functions in response to LPS were suppressed in the allograft. The findings will encourage the consideration of the effects of myeloid cells in the xenograft for drug development.
T 细胞缺陷型小鼠(如裸鼠)常用于生成肿瘤异种移植物,以开发抗癌药物。然而,异种移植物中其他免疫细胞(包括巨噬细胞、树突状细胞(DCs)和髓系来源抑制细胞(MDSCs))的功能在很大程度上尚不清楚。巨噬细胞和树突状细胞(DCs)在响应各种环境刺激时获得功能上不同的特性;这些细胞与肿瘤微环境中的 MDSCs 的相互作用调节癌症的进展。由于主要组织相容性复合体(MHC)不匹配,裸鼠不太可能排斥人癌细胞。异种移植物中的肿瘤微环境由人源和鼠源细胞组成,其双向信号转导和功能比同种异体移植物更为复杂。在这里,我们评估了它们之间髓样细胞的差异。脂多糖(LPS)给药后异种移植物肿瘤模型中的血浆干扰素-γ和白细胞介素-18 浓度明显高于同种异体移植物肿瘤模型。LPS 给药后,异种移植物肿瘤模型脾脏中 CD11b⁺和 MDSC 群体中的 MHC 类 I、II 和 CD80 表达水平增加,但同种异体移植物肿瘤模型中则没有。此外,LPS 给药后,异种移植物肿瘤中 CD80 和甘露糖受体 C 型 1(MRC1)表达细胞的数量减少。这些结果表明,巨噬细胞和 DCs 的功能在异种移植物中得以维持,而它们对 LPS 的反应功能在同种异体移植物中受到抑制。这些发现将鼓励考虑异种移植物中髓样细胞对药物开发的影响。